Incyte Corporation

INCY

US45337C1027

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

Pharmaceuticals

Calendar

2024-04-30 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Incyte Corporation : Is a big change imminent?

October 26, 2023 at 10:00 am EDT

More Strategies

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

53.43 USD

Average target price

76.06 USD

Spread / Average Target

+42.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
INCYTE CORPORATION	-14.91%	12B
CSL LIMITED	-4.17%	86.99B
SAMSUNG BIOLOGICS CO.,LTD.	+4.34%	40.68B
BIOGEN INC.	-23.95%	28.61B
UCB	+50.44%	24.1B
BIOMARIN PHARMACEUTICAL INC.	-5.09%	17.37B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-32.11%	13.72B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-5.10%	12.49B
SWEDISH ORPHAN BIOVITRUM AB	-3.30%	7.94B
INNOVENT BIOLOGICS, INC.	-18.83%	7.43B

Biopharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
53.43 ^USD	-0.78%		-2.94%	-14.91%

Apr. 01	Incyte, China Medical System Sign Collaboration, License Agreement	MT
Apr. 01	Incyte Corporation and China Medical System Holdings Limited Announce Collaboration and License Agreement for Povorcitinib, an Oral Jak1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	CI

Incyte, China Medical System Sign Collaboration, License Agreement	Apr. 01	MT
Incyte Corporation and China Medical System Holdings Limited Announce Collaboration and License Agreement for Povorcitinib, an Oral Jak1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	Apr. 01	CI
Trial of Insider Trading Case Against Former Medivation Employee Begins in California	Mar. 26	MT
Incyte's Povorcitinib Potentially Suited for Hidradenitis Suppurativa, Prurigo Nodularis, RBC Says	Mar. 12	MT
Transcript : Incyte Corporation - Shareholder/Analyst Call	Mar. 11
Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)	Mar. 10	CI
Transcript : Incyte Corporation Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 09:50 AM	Mar. 04
Wall Street: a flurry of records, including that of the Nasdaq 'broad	Mar. 01	CF
Wall Street: a flurry of records, including that of the Nasdaq 'large'.	Feb. 29	CF
Knight Therapeutics Announces Launch of Minjuvi in Brazil	Feb. 29	MT
Jefferies Initiates Incyte With Buy Rating, Price Target is $81	Feb. 23	MT
BMO Capital Adjusts Price Target on Incyte to $64 From $58, Keeps Market Perform Rating	Feb. 14	MT
Citigroup Adjusts Price Target on Incyte to $81 From $82, Keeps Buy Rating	Feb. 14	MT
JMP Securities Downgrades Incyte to Market Perform From Market Outperform	Feb. 14	MT
Truist Securities Adjusts Price Target on Incyte to $84 From $91, Maintains Buy Rating	Feb. 14	MT
Stifel Adjusts Price Target on Incyte to $68 From $67, Maintains Hold Rating	Feb. 14	MT
The market faces a choice	Feb. 14
RBC Lifts PT on Incyte to $65 From $63 on Model Updates Reflecting Monjuvi Integration, Slightly Improved Jakafi/Opzelura Sales Expectations; Sector Perform Kept	Feb. 14	MT
ANALYST RECOMMENDATIONS : Biogen, Gsk, Hp Inc, Palantir, Walt Disney...	Feb. 14
Incyte misses quarterly profit estimates due to higher costs	Feb. 13	RE
Incyte's Q4 Adjusted Earnings, Revenue Advance	Feb. 13	MT
Transcript : Incyte Corporation, Q4 2023 Earnings Call, Feb 13, 2024	Feb. 13
Earnings Flash (INCY) INCYTE Reports Q4 Revenue $1.01B, vs. Street Est of $1.00B	Feb. 13	MT
Earnings Flash (INCY) INCYTE Posts Q4 EPS $1.06, vs. Street Est of $1.15	Feb. 13	MT
Incyte Corporation Provides Earnings Guidance for 2024	Feb. 13	CI